Macrophage Pharma has appointed Dr Anker Lundemose as independent non-executive director.
The company says that the appointment will widen industry leadership perspective, as well as translational and commercial expertise.
Dr Anker is a Danish national and currently chief executive officer of Mission Therapeutics in Cambridge, UK. In a biopharma career spanning over 25 years, he will bring extensive international experience in areas of management, business development, corporate development, R&D strategy & execution, and financing.
Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: “On behalf of the Board I am pleased to welcome Anker as an independent director who has developed an outstanding reputation for having founded and built several successful companies within the European biotech sector.
“As MPL evolves into the next stage of its development Anker will prove a valuable resource in the translation of the products of our proprietary Esterase Sensitive Motif™ (ESM™) platform and in the formulation of commercial strategies to bring our macrophage-directed small molecule drugs to cancer patients and those with other serious diseases.”
